CURRICULUM DR.SSA SIMONA BURSI
INFORMAZIONI PERSONALI
NOME:
BURSI SIMONA
DATA DI NASCITA:
QUALIFICA:
INCARICO ATTUALE:
15/07/1980
MEDICO
NUM. TEL. UFFICIO:
FAX UFFICIO:
E-MAIL ISTITUZIONALE:
DIRIGENTE MEDICO, U.O ONCOLOGIA MEDICA, AZ USL 6
LIVORNO PRESIDIO DI LIVORNO
0586223458
0586223284
[email protected]
TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE
TITOLO DI STUDIO: LAUREA IN MEDICINA E CHIRURGIA (2004)
ALTRI TITOLI DI STUDIO E PROFESSIONALI: SPECIALIZZAZIONE IN ONCOLOGIA (2009)
ESPERIENZE PROFESSIONALI
(INCARICHI RICOPERTI):
DALL’ APRILE AL DICEMBRE 2009 È STATA TITOLARE DI UN CONTRATTO DELLA SOCIETÀ
ARCO FONDAZIONE RICECHE E CURE IN ONCOLOGIA O.N.L.U.S. PER LA REALIZZAZIONE
DI UN PROGETTO DAL TITOLO “VALUTAZIONE RETROSPETTIVA DELLO STATO MUTAZIONALE DI KRAS E DELLA DETERMINAZIONE IMMUNOISTOCHIMICA DI P-AKT, DI PTEN ED IGF-1R
QUALI FATTORI PREDITTIVI DI RISPOSTA AL TRATTAMENTO CON FARMACI TARGET-ORIENTED”.
DAL 16/05/2010 RICOPRE L'INCARICO DI DIRIGENTE MEDICO A TEMPO INDETERMINATO PRESSO
LA U.O. ONCOLOGIA MEDICA, AZ USL & LIVORNO – PRESIDIO DI LIVORNO. ATTUALMENTE
SI OCCUPA PREVALENTEMENTE DI NEOPLASIE DELL'APPARATO UROLOGICO MASCHILE E DI
MELANOMA
CAPACITA' LINGUISTICHE:
CAPACITÀ DI LETTURA:
LINGUA INGLESE
BUONO
CAPACITÀ DI SCRITTURA:
BUONO
CAPACITÀ DI ESPRESSIONE ORALE:
BUONO
CAPACITÀ NELL'USO DELLE TECNOLOGIE:
BUONO
ALTRO
Lavori in estenso su riviste internazionali con revisori e recensite
P1) First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the
feasibility and the activity of second line treatments in metastatic colorectal cancer. G. Masi, L. Marcucci, F.
Loupakis, E. Cerri, C. Barbara, S. Bursi, G. Allegrini, I.M. Brunetti, R. Murr, S. Ricci, S. Cupini, M.
Andreuccetti and A. Falcone. Ann Oncol, 17: 1249-54, 2006.
P2) Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of
metastatic colorectal cancer. G. Masi, E. Vasile, F. Loupakis, S. Bursi, S. Ricci, I. Petrini, A. Fontana, G.
Allegrini, A. Falcone. Clin Colorectal Cancer, 7: 7-14, 2008.
P3) A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan
in metastatic colorectal cancer. L. Fornaro, G. Masi, S. Bursi, F. Loupakis, E. Vasile, A. Antonuzzo, S.
Chiara, E. Pfanner, A. Di Paolo, G. Bocci, M. Del Tacca, A. Falcone. Cancer Chemother Pharmacol, 2009
Apr;63(5):965-9
P4) A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first
line treatment of metastatic colorectal cancer. E. Vasile, G. Masi, L. Fornaro, S. Cupini, F. Loupakis, S.
Bursi, I. Petrini, S. Di Donato, IM Brunetti, S. Ricci, A. Antonuzzo, S. Chiara, D. Amoroso, M.
Andreuccetti. A. Falcone. Br J Cancer, 2009 Jun 2; 100(11): 1720-4
P5) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and
dexamethasone in advanced hormone-refractory prostate cancer. A. Fontana, L. Galli, A. Fioravanti, P.
Orlandi, C. Galli, L. Landi, S. Bursi, G. Allegrini, E. Fontana, R. Di Marsico, A. Antonuzzo, M.
D’Arcangelo, R. Danesi, M. Del Tacca, A. Falcone, G. Bocci. Clin Cancer Res, 2009; 15(15) August 1,
2009
P6) Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.
Fontana A. Bocci G., Galli L., D'Arcangelo M., Derosa l., Orlandi A., Fioravanti P., Barletta MT, Landi L.,
Bursi S., Minuti G., Bona E., Grazzini I., Danesi R., Falcone A. J Am Geriatr Soc 2010 May 58(5):986-8
P7) Consequences of targeted treatments for second-line therapy. De Maio E., C. Tibaldi, A. D'Incecco, S.
Bursi, C. Barbara, Cupini S., R. Di Marsico, M. D'Arcangelo, L. Landi, G. Minuti, F. Cappuzzo. Ann Oncol
2010 Oct;21 Suppl 7:vii234-40.
Lavori in estenso su riviste in lingua italiana
P8) Il trattamento con 5-fluorouracile/acido folinico, oxaliplatino e irinotecano (FOLFOXIRI) consente di
riportare alla resezione chirurgica le metastasi di pazienti con carcinoma colorettale metastatico inizialmente
non resecabili. Treatment by FOLFOXIRI allows surgical resection of colon cancer metastases non
previously resectable. S. Bursi, G. Masi, F. Loupakis, S. Cupini, L. Marcucci, I. Brunetti, E. Pfanner, M. Viti,
L. Giuliani, F. Filippini, F. Mosca, A. Falcone. Acta Med Labronica, 3: 35-45, 2006.
ABSTRACTs
A1) Second line chemotherapy after first line folfoxiri in metastatic colorectal cancer (MCRC) patients
(PTS). L. Marcucci, S. Cupini, G. Masi, G. Allegrini, E. Cerri, F. Loupakis, S. Bursi, E. Fontana, A. Falcone.
Atti VII Congresso Nazionale G.O.N.O., Pisa, 17-18 Novembre: 51, 2005.
A2) Irinotecan (I) in associazione a capecitabina (C) seguiti da oxaliplatino (O) + C in pazienti (pz) anziani
vulnerabili con carcinoma colorettale metastatico (CCRM): risultati preliminari di uno studio multicentrico
di fase II. S. Bursi, E. Cerri, G. Masi, G. Allegrini, S. Cupini, L. Marcucci, F. Loupakis, C. Barbara, S. Ricci,
I. Brunetti, R. Murr, M. Andreuccetti, A. Falcone. Atti VII Congresso Nazionale G.O.N.O., Pisa, 17-18
Novembre: 30, 2005.
A3) Trattamento chemioterapico metronomico con iritotecano (CPT-11) in pazienti con diagnosi di
carcinoma colorettale metastatico: valutazione clinica e farmacodinamica. E. Cerri, G. Bocci, F. Loupakis, L.
Marcucci, S. Bursi, A. Fioravanti, P. Orlandi, A. Fontana, G. Masi, M. Andreuccetti, G. Allegrini, R. Danesi,
M. Del Tacca, A. Falcone. Atti VII Congresso Nazionale G.O.N.O., Pisa, 17-18 Novembre: 28, 2005.
A4) Capecitabine (C) in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) in patients with
metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest
(G.O.N.O.). S. Bursi, G. Masi, A. Antonuzzo, F. Loupakis, C. Barbara, M. Barletta, G. Allegrini, E. Pfanner,
R. Murr, A. Falcone. Proceedings 31st ESMO Congress, Istanbul, Turkey, 29 September – 3 October, 2006.
In: Annals of Oncology 17, Suppl 9, 2006.
A5) Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by
Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with
metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico
Nord Ovest (G.O.N.O.). F. Loupakis, G. Masi, E. Fontana, G. Allegrini, S. Bursi, C. Barbara, E. Cerri, M.T.
Barletta, V. Picone, L. Mentuccia, C. Granetto, E. Fea, E. Pfanner, R. Murr, I. Brunetti, M. Andreuccetti, A.
Falcone. Proceedings 8th National Congress of Medical Oncology, Milan, 18-21 November, 2006. In: Ann.
Oncol. 17 (Suppl. 11): xi50, 2006.
A6) Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with
metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest
(G.O.N.O.). S. Bursi, G. Masi, A. Antonuzzo, E. Cerri, F. Loupakis, C. Barbara, M. Barletta, G. Allegrini, S.
Cupini, S. Ricci, I. Brunetti, E. Pfanner, M. Lencioni, R. Murr, I. Petrini, L. Tognarini, M. Andreuccetti, A.
Falcone. Proceedings 8th National Congress of Medical Oncology, Milan, 18-21 November, 2006. In: Ann.
Oncol. 17 (Suppl. 11): xi41, 2006.
A7) Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV
(PFL) followed by irinotecan (IR) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients
(pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologico Nord-Ovest (GONO). F.
Loupakis, G. Masi, S. Bursi, V. Picone, L. Mentuccia, C. Granetto, E. Fea, R. Murr, A. Antonuzzo, A.
Falcone. Proceedings 43rd Annual Meeting American Society of Clinical Oncology (ASCO), Chicago,
Illinois, 1-5 June, 2007. In: JCO 25: 18S, 2007.
A8) The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line
treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo
Oncologico Nord-Ovest (G.O.N.O.). G. Masi, S. Bursi, F. Loupakis, M. Barletta, G. Baldi, A. Antonuzzo, C.
Sonaglio, E. Pfanner, I. Petrini, A. Falcone. Proceedings 43rd Annual Meeting American Society of Clinical
Oncology (ASCO), Chicago, Illinois, 1-5 June, 2007. In: JCO 25: 18S, 2007.
A9) Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated
results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study. A. Falcone, M.
Andreuccetti, S. Ricci, C. Orlandini, C. Barbara, W. Evangelista, L. Ciuffreda, E. Cortesi, R. Ferraldeschi, S.
Chiara, C. Granetto, F. Loupakis, S. Bursi, G. Allegrini, G. Masi. Proceedings 9th World Congress on
Gastrointestinal Cancer (WCGC), Barcelona, Spain, 28 June- 1 July, 2007. In: Ann Oncol 18, 2007.
A10) Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with
first-line folfoxiri followed by r0 surgical resection of metastases. G. Masi, S. Bursi, F. Loupakis, M.
Barletta, C. Barbara, E. Vasile, S. Cupini, I. Brunetti, E. Pfanner, S. Di Donato, G. D’Auria, L. Fanchini, S.
Chiara, C. Granetto, A. Falcone. Proceedings 9th World Congress on Gastrointestinal Cancer (WCGC),
Barcelona, Spain, 28 June- 1 July, 2007. In: Ann Oncol 18, 2007.
A11) First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine,
irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group. S.
Bursi, G. Masi, F. Loupakis, A. Antonuzzo, L. Tognarini, C. Sonaglio, S. Chiara, E. Pfanner, I. Brunetti, I.
Petrini, G. Baldi, M. Barletta, G. Allegrini, S. Ricci, A. Falcone. Proceedings 9th World Congress on
Gastrointestinal Cancer (WCGC), Barcelona, Spain, 28 June- 1 July, 2007. In: Ann Oncol 18, 2007.
A12) Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with
first-line FOLFOXIRI followed by R0 surgical resection of metastases. G. Masi, S. Bursi, F. Loupakis, C.
Barbara, I. Brunetti, R. Ferraldeschi, W. Evangelista, S. Chiara, C. Granetto, A. Falcone. Proceedings 14th
European Cancer Conference (ECCO), Barcelona, Spain, 23-27 September, 2007. In: EJC vol. 5, 4: 242,
2007.
A13) Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine
and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC). S. Cupini, S.
Bursi, G. Masi, F.Loupakis, C. Barbara, L. Fornaro, G. Allegrini, R. Di Marsico, M. Andreuccetti, A.
Falcone. Proceedings 14th European Cancer Conference (ECCO), Barcelona, Spain, 23-27 September, 2007.
In: EJC vol. 5, 4: 251, 2007.
A14) Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line
treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico NordOvest (G.O.N.O.). S. Bursi, G. Masi, F. Loupakis, A. Antonuzzo, S. Chiara, E. Pfanner, I. Petrini, M.T.
Barletta, G.G. Baldi, A. Falcone. Proceedings 14th European Cancer Conference (ECCO), Barcelona, Spain,
23-27 September, 2007. In: EJC vol. 5, 4: 255, 2007.
A15) Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic
colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final
report. M.T. Barletta, G. Bocci, F. Loupakis, A. Fioravanti, G. Baldi, P. Orlandi, , G. Allegrini, G. Masi, C.
Barbara, M. Andreuccetti, S. Cupini, S. Bursi, R. Danesi, A. Di Paolo, M. Del Tacca, A. Falcone.
Proceedings 9th National Congress of Medical Oncology (AIOM), Palermo, Italy, 12-15 October, 2007. In:
Ann Oncol 18 (suppl 11): xi4, 2007.
A16) Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in
elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC). S. Cupini, S. Bursi, G. Masi, F.
Loupakis, C. Barbara, M.T. Barletta, G.G. Baldi, E. Vasile, L. Fornaro, I. Petrini, G. Allegrini, A. Antonuzzo,
R. Di Marsico, M. Andreuccetti, S. Ricci, A. Falcone. Proceedings 9th National Congress of Medical
Oncology (AIOM), Palermo, Italy, 12-15 October, 2007. In: Ann Oncol 18 (suppl 11): xi6, 2007.
A17) First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ),
irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest
(G.O.N.O.). S. Bursi, G. Masi, F. Loupakis, A. Antonuzzo, L. Tognarini, C. Sonaglio, S. Chiara, E. Pfanner,
I. Brunetti, I. Petrini, G. G. Baldi, M.T. Barletta, L. Fornaro, G. Allegrini, S. Donati, M. Andreuccetti, S.
Ricci, A. Falcone. Proceedings 9th National Congress of Medical Oncology (AIOM), Palermo, Italy, 12-15
October, 2007. In: Ann Oncol 18 (suppl 11): xi6, 2007.
A18) First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal
cancer (MCRC) patients (pts). G. Masi, F. Loupakis, S. Bursi, C. Barbara, M.T. Barletta, G. Baldi, S. Cupini,
I. Brunetti, E. Pfanner, M. Lencioni, S. Di Donato, L. Mentuccia, L. Fanchini, C. Sonaglio, E. Fea, G.
Allegrini, A. Falcone. Proceedings 9th National Congress of Medical Oncology (AIOM), Palermo, Italy, 1215 October, 2007. In: Ann Oncol 18 (suppl 11): xi21, 2007.
A19) Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with
aggressive b-cell non-hodgkin’s lymphoma (NHL). E. Capochiani, S. Cupini, F. Loupakis, E. Vasile, A.
Fontana, C. Barbara, S. Bursi, L. Landi, L. Coltelli, V. Safina, M.T. Barletta, G.G. Baldi, N. Giuntini, M. Lo
Dico, E. Mazzoni, G. Masi, A. Falcone. Proceedings 9th National Congress of Medical Oncology (AIOM),
Palermo, Italy, 12-15 October, 2007. In: Ann Oncol 18 (suppl 11): xi67, 2007.
A20) Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and
celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II
clinical trial with pharmacodynamic evaluation. A. Fontana, G. Bocci, M. D’Arcangelo, L. Galli, C. Galli, S.
Bursi, L. Landi, A. Antonuzzo, M. Del Tacca, A. Falcone. Proceedings 44th Annual Meeting American
Society of Clinical Oncology (ASCO), Chicago, Illinois, 30 May - 3 June, 2008. In: JCO 26, 2008.
A21) Docetaxel (D) plus Prednisone (P) in combination with metronomic Cyclophosphamide (CTX) and
Celecoxib (C) as first line treatment in metastatic hormone refractory prostate cencer (MHRPC): A phase II
clinical trial with pharmacodynamic evaluation. A. Fontana, G. Bocci, M. D’Arcangelo, L. Galli, S. Bursi, L.
Landi, P. Battaglini, S. Caponi, M. Del Tacca, A. Falcone. Proceedings 33rd ESMO Congress, Stockholm,
Sweden, 12 – 16 September, 2008. In: Ann Oncol 19 (Suppl 8): viii198 – viii199, 2008.
A22) Il trattamento del carcinoma del colon-retto metastatico. Triplet combination of fluoropyrimidines,
oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. G. Masi, E. Vasile, F.
Loupakis, S. Bursi, S. Ricci, I. Petrini, A. Fontana, G. Allegrini, A. Falcone. Atti Giornata Regionale AIOM
Toscana, Sovigliana, Vinci (Firenze), 25 Settembre, 2008.
A23) Pegfilgrastim to support chop-r chemotherapy administered every 14 days in patients (PTS) with
aggressive B-cell non-Hodgkin’s lymphoma (NHL). S. Cupini, E. Capochiani, S. Bursi, L. Landi, L. Coltelli,
N. Giuntini, M. Lo Dico, E. Mazzoni, G. G. Baldi, M. T. Barletta, L. Fornaro, I. Stasi, A. D’Incecco, L.
Salvatore, S. Caponi, E. Bona, P. Battaglini, G. Masi, A. Falcone. Proceedings 10th National Congress of
Medical Oncology (AIOM), Verona, Italy, 11 – 14 October, 2008. In: Ann Oncol 19 (Suppl 9): ix9, 2008.
A24) Retrospective analysis of concomitant treatment with 3-dimensional conformal radiotherapy and
temozolomide in high-grade glioma patients. L. Landi, A. Fontana, C. Galli, L. Galli, S. Bursi, P. Battaglini,
S. Caponi, M. D’Arcangelo, R. Gagliardi, L. Benvenuti, M. Bosio, S. Capoccia, M. Andreuccetti, A. Falcone.
Proceedings 10th National Congress of Medical Oncology (AIOM), Verona, Italy, 11 – 14 October, 2008. In:
Ann Oncol 19 (Suppl 9): ix40, 2008.
A25) Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic
cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer
(MHRPC). A. Fontana, G. Bocci, M. D’Arcangelo, L. Galli, C. Galli, S. Bursi, L. Landi, A. Fioravanti, P.
Orlandi, P. Battaglini, S. Caponi, A. Antonuzzo, L. Derosa, G. Minuti, M. Andreuccetti, M. Del Tacca, A.
Falcone. Proceedings 10th National Congress of Medical Oncology (AIOM), Verona, Italy, 11 – 14 October,
2008. In: Ann Oncol 19 (Suppl 9): ix50, 2008.
A26) Low-dose metronomic cyclophosphamide (CTX) plus celecoxib (c) and dexamethasone (DEX) in
elderly patients (>78 years) with advanced castration resistant prostate cancer (CRPC). A. Fontana, G. Bocci,
L. Derosa, L. Galli, C. Galli, S. Bursi, P. Orlandi, S. Caponi, G. Minuti, A. Falcone. ASCO 2009
Genitourinary Cancers Symposium
A27) Phase II study of Docetaxel-Prednisone (DP) in combination with metronomic Cyclophosphamide
(CTX) and Celecoxib (C) as first line treatment in Castration Resistant Prostate Cancer (CRPC) patients
(Pts). A. Fontana, G. Bocci, L. Galli, L. Derosa, G. Minuti, M. D'Arcangelo, D. Santini, L. Landi, S. Bursi,
A. Falcone. In: J Clin Oncol 27, 2009 (suppl; abstr e16032).
A28) Pegfilgrastim to support R-CHOP q14 chemotherapy in the patients (PTS) with aggressive B-cell NonHodgkin’s lymphoma (NHL). E. Capochiani, S. Cupini. S. Bursi, L. Landi, L. Coltelli, N. Giuntini, M.
Barletta, G.G. Baldi, I. Stasi, A. Falcone. In: Haematologica 2009; 94(s2).
A29) Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with
metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate
cancer (CRPC). A. Fontana, L. Galli, L. Derosa, G. Minuti, M. D’Arcangelo, S. Bursi, L. Landi, G. Bocci, D.
Santini, A. Falcone. EJC Vol 7 No 2 September 2009
A30) Rituximab plus pegylated liposomal doxorubicin in combination with cyclophosphamide: a first line
therapeutic option for very elderly or unfit patients with aggressive non Hodgkin lymphoma. E. Capochiani,
S. Cupini, S. Bursi, S. Caponi, A. Falcone. In: Haematologica 2009; 94(s4).
A31) Docetaxel-Prednisone (DP) plus metronomic cyclophosphamide (CTX) and celecoxib (C) as first line
treatment in castration resistant prostate cancer (CRPC): phase II trial with pharmacodynamic evaluation. A.
Fontana, L. Galli, L. Derosa, G. Minuti, M. D’Arcangelo, E. Fontana, R. Di Marsico, O. Venditti. S.
Galluzzo, L. Landi, S. Bursi, C. Galli, E. Bona, G. Bocci, A. Antonuzzo, A. Falcone. In: Ann Oncol, Volume
20, 2009 Supplement 8
A32) Metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant
prostate cancer (CRPC): a phase II clinical study with pharmacokinetic (PK) and pharmacodynamic (PD)
evaluation. L. Galli, A. Fontana, L. Derosa, G. Minuti, M. D’Arcangelo, E. Fontana, V. Safina, L. Landi, S.
Bursi, C. Galli, E. Bona, G. Bocci, A. Antonuzzo, A. Falcone. In: Ann Oncol, Volume 20, 2009 Supplement 8